
Thank you for joining, we'll begin the call momentarily.



Laboratory Outreach Communication System (LOCS) Call

Monday, August 19, 2024, at 3:00 P.M. ET

Welcome

- Sean Courtney, CDC Division of Laboratory Systems
- SARS-CoV-2 Variants Update
 - Natalie Thornburg, CDC Coronavirus and Other Respiratory Viruses Division
- OneLab VR
 - Joe Rothschild, CDC Division of Laboratory Systems
- Dengue Update
 - Gilberto Santiago, CDC Division of Vector-Borne Diseases

About DLS



Four Goal Areas



Quality Laboratory Science

 Improve the quality and value of laboratory medicine for better health outcomes and public health surveillance



Highly Competent Laboratory Workforce

 Strengthen the laboratory workforce to support clinical and public health laboratory practice



Safe and Prepared Laboratories

 Enhance the safety and response capabilities of clinical and public health laboratories



Accessible and Usable Laboratory Data

 Increase access and use of laboratory data to support response, surveillance, and patient care

DLS ECHO Biosafety Program

- Date: August 27, 12:00 PM ET
- Topic: Operations Planning and Maintaining
- Speakers: Esmeralda Meyer, MD, JM, RBP (ABSA), CBSP (ABSA), BRM (IFBA), CPIA (PRIMR); Emory University
- For questions, contact <u>DLSbiosafety@cdc.gov</u>



Scan QR code to register

www.cdc.gov/safelabs/resources-tools/echo-biosafety.html

We Want to Hear From You!


Training and Workforce Development

Questions about education and training?

Contact LabTrainingNeeds@cdc.gov



LOCS Calls




On this page, you can find:

- LOCS Call information
- Transcripts
- Slides
- Audio Recordings

https://www.cdc.gov/locs/calls

How to Ask a Question

- Using the Zoom Webinar System
 - Click the Q&A button in the Zoom webinar system
 - Type your question in the Q&A box and submit it
 - Please do not submit a question using the chat button



- For media questions, please contact
 CDC Media Relations at media@cdc.gov
- If you are a patient, please direct any questions to your healthcare provider

Division of Laboratory Systems

Slide decks may contain presentation material from panelists who are not affiliated with CDC. Presentation content from external panelists may not necessarily reflect CDC's official position on the topic(s) covered.



Division of Laboratory Systems



Natalie Thornburg

CDC Coronavirus and Other Respiratory Viruses Division



Office of Laboratory Systems and Response



Laboratory Training: Virtual Reality (VR)

Laboratory Outreach Communication System (LOCS) Call August 19, 2024

Joe Rothschild

Virtual Reality Team Lead

Training and Workforce Development Branch Division of Laboratory Systems



Benefits of VR Training

Built-in Instructor

 One-on-one attention from a digital instructor who responds to individual actions, gives specific feedback, and teaches consistently across every learner experience

Mobility

 Headsets can be stored and transported to any location and are small enough to fit into a backpack. You can learn from anywhere all you need is an initial WiFi connection and a small space.

Knowledge Retention

• VR training delivers 3-4x higher information retention compared to traditional learning methods such as lectures, videos, or reading. Learners build confidence that translates to real job skills.

Accuracy of Content

 VR training is built in collaboration with SMEs, giving learners a true sense of the tasks and ensuring they're ready to work on day one.

Cost Effective

 Perform real-world training without an expensive physical facility or purchasing supplies for a training lab. CDC training simulations are updated with the latest equipment, regulations, and processes that are used on the job.



DLS VR Training Development Timeline

2019

- Began developing VR training
- Pilot-tested VR training with internal staff

2020

 Released CDC's first VR laboratory training course, "LabTrainingVR: Biosafety Cabinet Edition"

2021

- Released "LabTrainingVR: Personal Protective Equipment Edition"
- Developed multiplayer VR programming
- Created proof-of-concept for "OneLab VR" a virtual, multiplayer environment

2022

- Ported and released "LabTrainingVR: Biosafety Cabinet Edition" on Meta Quest
- Established Push-Pack Program
- Expanded "OneLab VR" programming and added multiplayer laboratory training



DLS VR Training Development Timeline

2023

- Launched OneLab VR
 - Tutorial Scenario
 - Packing and Shipping Dangerous Goods Scenario
- Updated OneLab VR with OpenXR compliance
 - Listed on SideQuest

2024

- OneLab VR Additions:
 - Desktop Micro Centrifuge Scenario
 - Swing Bucket Centrifuge Scenario
 - Autoclave Safety Scenario (TBD)
 - Updated Tutorial Scenario (TBD)

2025

- More OneLab VR scenarios
- Interagency partnerships
- ...and much, much more!




LabTrainingVR: Biosafety Cabinet Edition





https://reach.cdc.gov/course/labtrainingvr-biological-safety-cabinet-edition



https://www.youtube.com/watch?v=m92OQCAvQcs

Division of Laboratory Systems

LabTrainingVR: Personal Protective Equipment Edition





https://reach.cdc.gov/course/labtrainingvr-personal-protective-equipment-ppeedition



https://www.youtube.com/watch?v=ikq5-AUDrFQ

OneLab VR



50,000+ square feet of laboratory space with 100+ custom-built pieces of laboratory equipment including:

- Rotary microtome, tissue processors
- Dark field microscopes
- Incubators, refrigerators, freezers
- Real-Time PCR machines
- Centrifuges, microfuges
- Biosafety cabinets / fume hoods
- Chemistry analyzers
- Microbial identification systems
- And more...



OneLab VR Walkthrough



VR-Ready Laboratories Program



Meta Quest 3



2022 Pilot (Push-Pack Phase 1):

• Sent out 40 headsets

2022 (Push-Pack Phase 2):

• Sent out **120** headsets

2023 (Push-Pack & VR-RLP Started):

• Sent out **137** headsets

2024 (VR-RLP):


• Sent out **115** headsets



VR-Ready Laboratories Program








CDC Laboratory Training Website





reach.cdc.gov

Questions?

For more information, contact CDC 1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

Images used in accordance with fair use terms under the federal copyright law, not for distribution.

Use of trade names is for identification only and does not imply endorsement by U.S. Centers for Disease Control and Prevention.

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of Centers for Disease Control and Prevention.





Centers for Disease Control and Prevention National Center for Emerging and Zoonotic Infectious Diseases



Laboratory Readiness for Dengue Testing During an Epidemic

Gilberto A. Santiago, PhD

Laboratory Team Lead (Acting)


Dengue Branch

Dengue Viruses (DENVs)

- DENV-1, 2, 3, 4
 - Lifelong DENV type-specific immunity
 - Short-term cross-immunity (~1–2 years)
 - Individuals can be infected up to 4 times in their life.

Clinical Course


- ~3 in 4 DENV infections are asymptomatic.
- If symptomatic, onset occurs abruptly after an incubation period of 5–7 days (Range: 3–10).
- Early clinical findings are non-specific
 - Can be difficult to distinguish from other pathogens.
- Can be life-threatening
- Specific "warning signs" predict progression to severe disease




Dengue 1



Dengue 3



Dengue 2



Dengue 4

DENV Transmission

- Vector-borne
 - Saliva of infected Aedes spp. mosquito

Other modes

- Vertical from mother to baby
- Blood transfusion or organ transplantation
- Needle stick, mucocutaneous, or hospital/laboratory accident
- Breast milk



Aedes aegypti



Aedes albopictus

Mosquito Vector Geographical Range

Dengue vectors are present across much of the US.



Estimated Potential Range of Aedes albopictus in the United States, 2017



WHO Global Dengue by the Numbers

2023

2024 (up to July)



• **5 million cases** reported worldwide

• 10.9 million cases reported worldwide



- 80 countries/territories reporting cases
 - All 6 WHO regions

- >90 countries/territories reporting cases
 - All 6 WHO regions




• **5,000** dengue related deaths

• **6,000** dengue related deaths

Dengue cases in the Americas, 1980–2024*

More than 10.9 million cases reported as of August 2024




^{*}Data from PAHO PLISA Health Information Platform for the Americas. https://www3.paho.org/data/index.php/es/temas/indicadores-dengue.html. Accessed 8/6/2024



Among dengue cases reported to ArboNET from 2010–2022,

most dengue cases in U.S. states (>94%) were associated with travel to endemic areas.

Travel associated dengue cases reported in the US by week, 2024 and comparison years*




^{*}Data from: Data and Statistics on Dengue in the United States | Dengue | CDC. Accessed 8/4/2024. Cases for 2023 and 2024 are preliminary.

Locally Acquired Dengue in US States, 2010-2024

- Sporadic cases historically limited to outbreaks in:
 - Florida, Hawaii, Texas

- Recently, more states are reporting local DENV transmission.
 - Arizona, n=2 (2022)
 - California, n=2 (2023)



Increased Risk of Dengue Virus Infections in the United States


Print





Distributed via the CDC Health Alert Network June 25, 2024, 2:30 PM ET CDCHAN-00511

Acute and Convalescent Phase




Laboratory testing is most sensitive when performed within the first 7 days of illness.

• Within 7 days of symptom onset, test with:

RT-PCR + IgM ELISA or NS1 antigen ELISA + IgM ELISA

Using this test combination provides a laboratory diagnosis in >90% of dengue cases.*



For more information on testing, visit: www.cdc.gov/dengue/healthcare-providers/testing/

Testing >7 days After Illness Onset


Test with:

IgM serology

and consider (optional)*

NS1 antigen ELISA or RT-PCR

(lower sensitivity compared to days 0–7)



^{*}Testing guidance may vary by jurisdiction, especially in endemic areas.

For more information on testing, visit: www.cdc.gov/dengue/healthcare-providers/testing/

Public health labs can run FDA approved IgM, CDC RT-PCR, or NS1 tests.

Test	FDA approval	Commercially available	Public health labs
CDC DENV-1-4 RT-PCR	IVD (510k)	No	Yes
CDC Trioplex RT-PCR (ZIKV, DENV, CHIKV)*	IVD (EUA)	No	Yes
InBios IgM ELISA*	IVD (510k)	Yes	Tests can be purchased
InBios NS1 ELISA*	IVD (510k)	Yes	Tests can be purchased

^{*}**Does not** identify DENV type. CDC DENV-1–4 RT-PCR testing or Plaque Reduction Neutralization Tests (PRNT) will identify DENV type.

Private labs can purchase commercially available FDA approved IgM and NS1 antigen tests.

Test	FDA approval	Commercially available	Public health labs	Private labs
CDC DENV-1-4 RT-PCR	IVD (510k)	No	Yes	No
CDC Trioplex RT-PCR (ZIKV, DENV, CHIKV)	IVD (EUA)	No		No
InBios IgM ELISA*	IVD (510k)	Yes	Test can be purchased	Tests can be purchased
InBios NS1 ELISA*	IVD (510k)	Yes		Tests can be purchased

^{*}Does not identify DENV type. CDC DENV-1-4 RT-PCR testing or Plaque Reduction Neutralization Tests (PRNT) will identify DENV type.

Characteristics of the CDC RT-PCR Tests

Intended use

• For use with samples taken from **symptomatic** patients.

Pathogen	Trioplex	DENV-1-4
Zika virus (ZIKV)	✓	
chikungunya virus (CHIKV)	✓	
dengue virus (DENV)	✓	
• DENV-1		✓
• DENV-2		✓
• DENV-3		✓
• DENV-4		✓

Specimen type	Trioplex	DENV-1-4
Serum	✓	✓
Plasma	✓	✓
Urine*¥	✓	
Whole blood (EDTA)*	✓	
CSF*	✓	
Amniotic fluid*¥	✓	



*must be tested alongside a patient-matched serum sample ¥ for Zika testing only

Equipment validated for use with CDC RT-PCR Tests

Process	Trioplex RT-PCR test CURRENT	DENV-1-4 RT-PCR Test CURRENT
RNA extraction	MagNA Pure LC*(Roche)	MagNA Pure LC (Roche) *
	MagNA Pure 96 (Roche)	
	MagNA Pure Compact* (Roche)	
	NucliSENS easyMAG (bioMérieux)	
PCR Cyclers	ABI7500 Fast Dx [*] (ThermoFisher)	ABI7500 Fast Dx* (ThermoFisher)
	QuantStudio Dx [*] (ThermoFisher)	

^{*} Equipment is or will be discontinued by the vendor

Future

Equipment validated for use with CDC RT-PCR Tests

Process	Trioplex RT-PCR test CURRENT	DENV-1-4 RT-PCR test CURRENT	Trioplex and DENV-1-4 RT-PCR FUTURE
RNA extraction	MagNA Pure LC*(Roche)	MagNA Pure LC (Roche) *	KingFisher Apex (ThermoFisher)
	MagNA Pure 96 (Roche)		MagNA Pure 96 (Roche)
	MagNA Pure Compact* (Roche)		
	NucliSENS easyMAG (bioMérieux)		
PCR Cyclers	ABI7500 Fast Dx [*] (ThermoFisher)	ABI7500 Fast Dx* (ThermoFisher)	QuantStudio Dx (ThermoFisher)
	QuantStudio Dx (ThermoFisher)		QuantStudio 5 Dx (ThermoFisher)

^{*} Equipment is or will be discontinued by the vendor

Example format for presenting test results and interpretations

Test	Analyte	Result	Interpretation
CDC DENV-1-4 Real Time RT-PCR Assay	Dengue 1 RNA detection by rRT-PCR	Negative	No dengue type 1 RNA detected
	Dengue 2 RNA detection by rRT-PCR	Negative	No dengue type 2 RNA detected
	Dengue 3 RNA detection by rRT-PCR	Negative	No dengue type 3 RNA detected
	Dengue 4 RNA detection by rRT-PCR	Negative	No dengue type 4 RNA detected

	Result	Interpretation
	Positive	Current dengue virus type 1 infection
	Positive	Current dengue virus type 2 infection
or	Positive	Current dengue virus type 3 infection
	Positive	Current dengue virus type 4 infection

Test	Analyte	Result	Interpretation
Dengue InBios IgM	Dengue IgM final result	Negative	No dengue IgM antibody detected

Result	Interpretation
Positive	Recent dengue virus infection

or

Ordering Information for CDC RT-PCR Testing

Contact us to request tests!

• Send requests for Trioplex to:

trioplexPCRordering@cdc.gov

Send requests for DENV-1–4 (serotyping) to:

denguePCRordering@cdc.gov




Include the following information in your message:

- Laboratory name and address
- Qualified contact person
- Phone number
- Email address
- Shipping address

Best practices for sending samples to CDC

- Review specimen handling and shipping in the <u>CDC Test Directory</u>
- Request testing through CSTOR Web Portal (for public health labs).
- If not using CSTOR...
 - **Complete** CDC Form 50.34.
 - **Send** with the sample.
 - Contact CDC lab before sending sample.



Don't forget:

- Recognize dengue in your emergency rooms
- Know the warning signs for progression to severe dengue
- Test appropriately for dengue

For more information, contact CDC 1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

Gilberto A. Santiago , PhD

GSantiago@cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.





Monday, September 16 3 PM - 4 PM ET



https://www.cdc.gov/locs/calls

CDC Social Media

https://www.facebook.com/CDC






https://x.com/cdcgov





https://www.linkedin.com/company/cdc

Thank You For Your Time!





For more information, contact CDC 1-800-CDC-INFO (232-4636) TTY: 1-888-232-6348 www.cdc.gov

Images used in accordance with fair use terms under the federal copyright law, not for distribution.

Use of trade names is for identification only and does not imply endorsement by U.S. Centers for Disease Control and Prevention.

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of Centers for Disease Control and Prevention.